Viridian Therapeutics, Inc. (VRDN) SEC Filings & Earnings Calls

Commercial execution risk for Lumvoa launch; early but unquantified revenue.

“Early launch feedback positive but no revenue reported yet.”

High cash burn rate: net loss $127.1M in Q2; SG&A ramp for commercial infrastructure.

“Net loss $127.1M; SG&A $55.0M up 172% YoY.”

Cash burn and going concern risk

“We may need to secure additional capital to continue to fund our operations and service our obligations in the future. If we are unable to secure additional capital when needed, we will not be able to continue as a going concern.” · word for word

Clinical trial failure risk

“Clinical development is expensive, time consuming, and involves significant risk. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all.” · word for word

Regulatory approval risk

“Failure to obtain regulatory approval for our product candidates would have a material adverse effect upon our business and business prospects.” · word for word

FDA disruption risk

“A significant reduction in FDA’s workforce or FDA’s budget, or other disruptions at FDA, could materially impact FDA’s ability to engage in a variety of activities that may affect our business, including routine regulatory and oversight activities.” · word for word

Product liability risk

“If the use or misuse of our approved product or product candidates harm patients or subjects, or is perceived to harm patients or subjects even when such harm is unrelated to our approved product or product candidates, our regulatory approvals, could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability” · word for word

Cash burn rate; no revenue yet; reliance on regulatory approval and commercial success

“Cash decreased from $874.7M to $762.2M in Q1; R&D and SG&A expenses increasing as company prepares for launch.”

Regulatory risk: veligrotug PDUFA in June 2026; no guarantee of approval

“Veligrotug BLA under Priority Review with PDUFA target action date of June 30, 2026.”

Regulatory and commercial risks remain; BLA approval not guaranteed.

“forward-looking statements caution about regulatory approvals and competition”

Clinical trial failure risk

“Clinical development is expensive, time consuming, and involves significant risk. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all.” · word for word

Regulatory approval delay risk

“The FDA or other regulatory authorities may require additional patients in this safety database or may require us to take other additional steps.” · word for word

Capital requirement risk

“We may need to secure substantial additional capital to continue to fund our operations in the future.” · word for word

Clinical and regulatory risk for veligrotug and elegrobart

“We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases.” · word for word

Dependence on Fairmount as major stockholder and related-party transactions

“Entities affiliated with Fairmount Funds Management LLC 16,025,330 15.7 %” · word for word

No revenue and net losses

“Net Income (6) 2025 ... $ ( 342.6 )”

Clinical trial results may not lead to regulatory approval or commercial success; competition from veligrotug and other therapies.

“Forward-looking statements caution about regulatory and commercial uncertainties.”

Regulatory approval risk for veligrotug; PDUFA date June 30, 2026.

“BLA under Priority Review; no guarantee of approval.”

Clinical trial risk for elegrobart; REVEAL-1 and REVEAL-2 data pending.

“Topline data expected Q1 and Q2 2026; could fail to meet endpoints.”

Commercial execution risk; company has no prior commercial experience.

“Pre-commercial stage; building sales force and market access.”

Cash burn rate; net loss increasing as company invests in R&D and commercial prep.

“Net loss $342.6M in 2025 vs $269.9M in 2024; R&D and SG&A expenses rising.”

Single CDMO dependency (WuXi)

“We currently rely on a single multi-site CDMO for manufacturing our clinical materials, WuXi Biologics (Hong Kong) Limited ("WuXi"), although other avenues remain available if our current manufacturer were to be negatively impacted.” · word for word

Drug pricing and regulatory pressure

“The Inflation Reduction Act of 2022 ("IRA") included a number of changes relevant to drug prices in Medicare Parts B and D, including caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D inflationary rebates, a new Medicare Part D manufacturer discount drug program (replacing the previous coverage gap discount program) and a drug price neg” · word for word

Clinical trial and regulatory uncertainty

“The process of conducting clinical trials and nonclinical studies necessary to obtain regulatory approval is costly and time consuming.” · word for word

Cash runway risk

“We expect that our current cash, cash equivalents and short-term investments, will enable us to fund our planned operations for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements.” · word for word

Regulatory approval risk

“We may not be able to receive approval to market any of our current or future product candidates from regulatory authorities in our desired indications in any jurisdiction, and it is possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.” · word for word

FDA workforce disruption risk

“A significant reduction in FDA’s workforce or FDA’s budget, or other disruptions at FDA, could materially impact FDA’s ability to engage in a variety of activities that may affect our business, including routine regulatory and oversight activities.” · word for word

FDA approval risk for veligrotug; commercial launch execution risk.

“if approved under a Priority Review timeline” · word for word